Myasthenia Gravis
Welcome,         Profile    Billing    Logout  
 64 Companies   21 Products   21 Products   23 Mechanisms of Action   207 Trials   10745 News 


«12...7273747576777879808182...136137»
  • ||||||||||  Trial completion, Enrollment change:  Neurology Inpatient Clinical Education Trial (clinicaltrials.gov) -  Jan 11, 2022   
    P=N/A,  N=50, Completed, 
    These observations need to be validated in a larger sample. Active, not recruiting --> Completed | N=80 --> 50
  • ||||||||||  Review, Journal:  Cholinesterases in Tripartite Neuromuscular Synapse. (Pubmed Central) -  Jan 11, 2022   
    This will be followed by a look at the role of TSC in synaptic transmission. Finally, we will review the pathological conditions where there is evidence of decreased AChE activity.
  • ||||||||||  Journal:  New insights into very-late-onset myasthenia gravis. (Pubmed Central) -  Jan 7, 2022   
    Recruiting --> Active, not recruiting | N=20 --> 29 | Trial completion date: Dec 2021 --> Jul 2022 | Trial primary completion date: Oct 2021 --> Feb 2022 No abstract available
  • ||||||||||  Clinical, Review, Journal, IO biomarker:  Advances and challenges in the treatment of myasthenia gravis. (Pubmed Central) -  Jan 7, 2022   
    The review gives an overview on new drugs being evaluated in still ongoing or recently finished controlled clinical trials and drugs of potential benefit in MG due to their mechanisms of action and positive effects in other autoimmune disorders. Also, the challenges associated with the new therapeutic options are discussed briefly.
  • ||||||||||  Journal:  Calcification in thymomas can predict invasiveness to surrounding organs. (Pubmed Central) -  Jan 5, 2022   
    Calcification reflects invasiveness of tumors to surrounding organs and tissues, and may thus predict thymoma stage and histologically high-risk thymomas. Calcification in thymomas may also predict the pathological stage and help decide therapeutic methods and surgical approaches to treat thymomas based on the calcification status according to CT findings.
  • ||||||||||  Clinical, Journal:  Swallowing dysfunction in myasthenia gravis patients examined with high-resolution manometry. (Pubmed Central) -  Jan 5, 2022   
    Calcification in thymomas may also predict the pathological stage and help decide therapeutic methods and surgical approaches to treat thymomas based on the calcification status according to CT findings. The chin-down position appears useful for improving pharyngeal clearance in MG patients, by promoting increased SP at the meso‑hypopharynx, relaxing SP at the UES, and increasing the duration of relaxation pressure at the UES.
  • ||||||||||  Retrospective data, Review, Journal:  Is myasthenia gravis a contraindication for botulinum toxin? (Pubmed Central) -  Jan 5, 2022   
    In contrast, 10 patients presenting MG as comorbidity had received BTX for dystonia or overactive bladder ("BTX injection after MG diagnosis"), and 8 out of 10 (80%) experienced improved symptoms through appropriate dose modifications and adequate treatment for MG before receiving BTX injections. These findings support that, under proper management of co-existing MG, BTX could be used safely and successfully in patients presenting MG comorbidities in the future.
  • ||||||||||  Journal:  Neurologic Toxicities of Immunotherapy. (Pubmed Central) -  Jan 4, 2022   
    Early recognition of these neurological syndromes, timely diagnosis, and thoughtful management are key for further clinical development of these effective therapies in cancer patients. Here, we describe clinical phenotypes of CPI-induced neurological complications and ICANS and discuss steps in clinical monitoring, diagnosis, and effective management.
  • ||||||||||  Clinical, Journal:  The effects of spinal stabilization exercises in patients with myastenia gravis: a randomized crossover study. (Pubmed Central) -  Jan 4, 2022   
    FSS, VAFS, muscle strength, 6MWT, MGQOL-15 values were found significantly different in SSE group (p = .005 in all parameters). SSE are safe and effective on fatigue, muscle strength, respiratory functions, functional capacity, and QoL for MG patients, so it may be suggested to include SSE in rehabilitation programs of MG patients.Implications For RehabilitationSpinal stabilization exercises are safe and effective for Myasthenia Gravis patients.Home exercise program which included breathing exercises and callisthenic exercises tailored to the patients' needs is safe and effective for Myasthenia Gravis patients.Rehabilitation programs of Myasthenia Gravis patients should include spinal stabilization exercises.
  • ||||||||||  Review, Journal:  An overview of recent analysis and detection of acetylcholine. (Pubmed Central) -  Dec 30, 2021   
    In the paper, the pathophysiological functions and the comprehensive research progress on detection methods of ACh are summarized. Specifically, the latest research and related applications of the optical and electrochemical biosensors are described, and the future development directions and challenges are prospected, which provides a reference for the detection and applications of ACh.
  • ||||||||||  Review, Journal:  Single-cell approaches to investigate B cells and antibodies in autoimmune neurological disorders. (Pubmed Central) -  Dec 29, 2021   
    High-resolution single-cell methods have revealed abnormalities in the tolerance mechanisms of several disorders and provided further insight into the B cells responsible for autoantibody production. Ultimately, several factors, including epitope specificity and binding affinity, finely regulate the pathogenic potential of an autoantibody, and a deeper appreciation of these factors may progress the development of targeted immunotherapies for patients.
  • ||||||||||  Journal:  Neuromuscular complications of coronavirus disease-19. (Pubmed Central) -  Dec 25, 2021   
    COVID-19 appears to be potentially associated with a wide range of neuromuscular manifestations and complications. Further studies are needed to examine these possible associations, understand the pathogenesis, and develop preventive and treatment strategies.
  • ||||||||||  Journal:  High levels of serum interleukin-6 are associated with disease activity in myasthenia gravis. (Pubmed Central) -  Dec 25, 2021   
    The serum levels were correlated with the MG Foundation of America clinical classification (Spearman's ρ = 0.27; P < 0.01) and decreased following immunosuppressive treatment in parallel with disease activity (P = 0.01). In conclusion, IL-6 is involved in the pathogenesis of anti-AChR antibody-positive MG and could be a therapeutic target in MG.
  • ||||||||||  Review, Journal:  The pathogenic, therapeutic and diagnostic role of exosomal microrna in the autoimmune diseases. (Pubmed Central) -  Dec 25, 2021   
    In the present study, we summarized the pathogenic role of exosomal miRNAs in several autoimmune diseases, including myasthenia gravis (MG), psoriasis, inflammatory bowel disease (IBD), type 1 diabetes (T1D), multiple sclerosis (MS), systemic lupus erythematosus (SLE), rheumatoid arthritis (RA), Sjogren's Syndrome (SS), systemic sclerosis (SSc), vitiligo, and autoimmune thyroid diseases (AITD). Moreover, in this work, we present evidence of the potential role of exosomal miRNAs as therapeutic and diagnostic agents in autoimmune diseases.
  • ||||||||||  Clinical, Journal:  Sexual dysfunction in patients with myasthenia gravis. (Pubmed Central) -  Dec 25, 2021   
    SD is a common problem in MG, and its severity does not change with the severity of the disease. Age and depression are risk factors for sexual dysfunction.
  • ||||||||||  Clinical, Journal:  Acetylcholine receptor antibodies in a patient with sensory neuropathy. (Pubmed Central) -  Dec 25, 2021   
    Antibodies to acetylcholine receptor (AChR) are detected in the vast majority of patients with generalized myasthenia gravis (MG) and are rarely detected in significant titer in other autoimmune diseases. We report a patient with an axonal predominately sensory neuropathy for over 12 years with persistent binding and modulating AChR antibodies as well as striational muscle antibodies with no evidence of MG or any neoplastic disease.
  • ||||||||||  Soliris (eculizumab) / AstraZeneca
    Clinical, Review, Journal:  Clinical Efficacy and Safety of Eculizumab for Treating Myasthenia Gravis. (Pubmed Central) -  Dec 25, 2021   
    In this review, we have discussed the treatment time, cost effectiveness, long-term efficacy, and tolerability of eculizumab for MG treatment. We have also summarized historical information and have presented perspectives on this new therapeutic modality.
  • ||||||||||  prednisone / Generic mfg.
    Clinical, Journal:  Fracture Risk in Patients with Myasthenia Gravis: A Population-Based Cohort Study. (Pubmed Central) -  Dec 22, 2021   
    In this large, population-based cohort of incident MG patients, MG patients were at lower risk of a major fracture than comparators. The reasons for this finding are unclear but may highlight the importance osteoporosis prevention.
  • ||||||||||  Clinical, Journal:  Fatigue, physical activity and associated factors in 779 patients with myasthenia gravis. (Pubmed Central) -  Dec 22, 2021   
    Higher level of physical activity was associated with lower levels of fatigue. Important factors for the association were myasthenia gravis disease severity (measured by the Myasthenia Gravis Activities of Daily Living profile), body mass index, insomnia (measured by the Insomnia Severity Index) job-status, comorbidity, and cohabitation.
  • ||||||||||  Clinical, Journal:  Home-based exercise in autoimmune myasthenia gravis: A randomized controlled trial. (Pubmed Central) -  Dec 22, 2021   
    Although exercise was well tolerated, the intention-to-treat analysis revealed no evidence of improved HRQoL compared to usual care (MGQOL-15-F; mean adjusted between-groups difference of -0.8 points, 95%CI -5.4 to 3.7). Two patients hospitalized for MG exacerbation were from the usual care group.